streptokinase IU ml-, P = 0.02). There were trends towards a higher streptokinase resistance titre in those patients with coronary occlusion at 90 minutes (50 v 20 streptokinase IU ml-, P = 0.06) and higher concentrations of IgG antibodies to streptokinase in those with coronary occlusion at both 90 minutes and 24 hours (1.53 v 0'925, P = 0-03; 1-65 v 1'04 ug streptokinase binding ml-', P = 0.06).
Patients-One hundred and twenty four previously unexposed patients presenting within six hours of onset of acute myocardial infarction. Interventions-Streptokinase, 1P5 MIU as intravenous infusion over 60 minutes (60 patients), or anistreplase, 30 units as intravenous injection over five minutes (64 patients). Main outcome measures-Pretreatment streptokinase resistance titre and concentration of IgG antibodies to streptokinase were measured in 96 and 124 patients respectively and coronary patency assessed angiographically at 90 minutes and 24 hours. Results-Pretreatment streptokinase resistance titre and concentrations of IgG antibodies to streptokinase were low and skewed towards higher values. Those patients with coronary occlusion at 24 hours had a significantly higher median streptokinase resistance titre (100 v 50 streptokinase IU ml-, P = 0.02). There were trends towards a higher streptokinase resistance titre in those patients with coronary occlusion at 90 minutes (50 v 20 streptokinase IU ml-, P = 0.06) and higher concentrations of IgG antibodies to streptokinase in those with coronary occlusion at both 90 minutes and 24 hours (1.53 v 0'925, P = 0-03; 1-65 v 1'04 ug streptokinase binding ml-', P = 0.06).
Coronary patency rates were similar in the two treatment groups.
Conclusions-In the range measured in previously unexposed patients the streptokinase resistance titre has a small, but significant, negative influence on the efficacy of streptokinase and anistreplase. Thrombolytic drugs containing streptokinase cause an antibody response that persists in the circulation for at least 4 years. '8 19 Although it has been suggested that high antibody concentrations are associated with a loss of efficacy"3 14 Patients and methods One hundred and twenty eight consecutive patients were recruited who had presented within six hours of the onset of symptoms of myocardial infarction. They had had chest pain for at least 30 minutes, and did not have any of the standard contraindications to thrombolytic treatment2l or coronary angiography; evaluable data were obtained in 124 patients. All patients had at least 1 mm of ST elevation in two limb leads, or at least 2 mm ST elevation in two precordial leads. Patients older than 70 years, or those who had had a previous myocardial infarction in the same anatomical distribution, or who had previously received thrombolytic treatment, were excluded. After discussion with the patient and attending relatives, written informed consent was obtained.
The mean (SD) age of our patients was 55-6 (8 3) years, with a range of 31-70 years. Anti-SK IgG (gg SK binding/ml)
Frequency histograms of (A) pretreatment streptokinase resistance titre (SKRT) and (B) concentrations ofIgG antibodies to streptokinase (SK). Analysis of the streptokinase and anistreplase treated groups separately showed consistent trends towards higher concentrations of IgG antibodies to streptokinase and minor trends towards a higher streptokinase resistance titre in those patients with persistent coronary occlusion.
Further analysis of TIMI grade 3 compared with TIMI grades 0-2 at the two time points, as suggested by other studies,25 showed similar trends towards a higher streptokinase resistance titre and concentrations of IgG antibodies to streptokinase in those patients with less complete perfusion. These trends achieved conventional levels of significance when concentrations of IgG antibodies to streptokinase were compared in those patients with TIMI grades 0-2 and TIMI grade 3 perfusion at 24 hours (1-65 v 0-92, P = 0-03).
Discussion
The exact prevalence of antibodies to streptococcal protein and resistance to streptokinase in the community remains largely undefined.
It has been suggested"'34 that high levels of resistance to streptokinase may negate the efficacy of streptokinase administered to establish a lytic state for the treatment of disorders such as myocardial infarction. With increasing administration, and possible repeat administration, of thrombolytic treatment for this indication, it is important to define the relevance of resistance to thrombolytic drugs containing streptokinase.
The most commonly prescribed thrombolytic drug in the United Kingdom is streptokinase, and therapeutic administration of this drug and anistreplase is known to stimulate the development of antibodies to the streptokinase moiety,'826 which to date have been shown to persist in the circulation for at least 4 years.'9 The relevance of this response remains undefined.
In this study we examined the influence of Withinthe range of these measured variables, the streptokinase resistance titre has a small, but demonstrable, influence on the efficacy of the thrombolytic drugs containing streptokinase. There was a significantly higher streptokinase resistance titre in patients with TIMI grades 0 and 1 at 24 hours, and trends towards higher streptokinase resistance titres in the comparable group for TIMI grades 0 and 1 at 90 minutes. There were also trends towards higher concentrations of IgG antibodies to streptokinase in these groups.
The differences are relatively minor and consistent with some previous studies which concluded that the efficacy of these drugs is not substantially influenced by the concentration of IgG antibodies to streptokinase,16 17 
